• Ema: with Omicron, vaccines will continue to protect.

    "The references are fundamental"

  • Vaccines, Ema recommends Pfizer use for children 5-11 years old

  • Covid: Ema, authorization requested for the Merck pill

Share

09 December 2021 "The current recommendation is to administer the booster dose preferably after 6 months. The available data support the safe and effective administration of a booster dose as early as 3 months after completion of the primary vaccination". Marco Cavaleri from the EMA said this during the briefing.



"It is too early to say whether adaptations from current Covid vaccines to the Omicron variant will be needed," Cavaleri later explained. "Preliminary data show that there is a considerable drop in the ability of vaccinated or cured people to reject the Omicron variant of Covid. But we need more data to be able to determine the level of immunity provided by vaccines against the variant." "At present we have no data on effectiveness of vaccines against this variant, "he added.



"Companies marketing Covid-19 vaccines are required to submit laboratory test results to determine the neutralization level for Omicron. We are ready to act quickly when needed," he stressed. And he added: "The epidemiological situation in Europe is still extremely worrying due to the spread of the Delta variant". 



Infections and hospitalizations of children between the ages of 5 and 11


on the rise Infections and hospitalizations for covid children between the ages of 5 and 11 "are increasing in


recent months ", explains Cavaleri" All children of this age group must be considered for vaccination, even if priority must be given to subjects at risk of contracting severe forms of covid ", it is specified." vaccines for this age group are reassuring.

At the moment, no safety concerns have emerged from the vaccination campaign extended in the US ".


Epidemiological data show that infections & hospitalization of children aged 5-11 years have been on the rise in recent months.

While children at risk of severe # COVID19 should be given priority, all children in this age group should be considered for vaccination.

#EMAPresser

- EU Medicines Agency (@EMA_News) December 9, 2021


Novavax evaluation possible by the end of the year "


" We could conclude the evaluation of the Novavax vaccine against Covid before the end of the year "finally said the head of the EMA vaccination strategy.